Jade Biosciences

Jade Biosciences

Jade Biosciences was formed as a clinical-stage company to develop next-generation therapies for autoimmune diseases. The firm's pipeline is sourced from discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. Chief Executive Officer Tom Frohlich leads the Philadelphia-based operation alongside a board that includes Eric Dobmeier of Samsara Biocapital and Tomas Kiselak, a founding partner at Fairmount. The company's lead candidate, JADE101, is an inhibitor of the cytokine APRIL — a proliferation-inducing ligand — purpose-built for immunoglobulin A nephropathy (IgAN). Jade’s strategic focus is on redefining standards of care in targeted autoimmune indications, using an asset-acquisition model rather than internal discovery. No public disclosures describe additional portfolio assets beyond JADE101 or other therapeutic areas of active engagement. The geographic focus remains on clinical development in US markets. The leadership team includes President of R&D Andrew King and Chief Medical Officer Edward R. Conner, supported by senior executives covering finance, legal, regulatory, biometrics, and development operations. The board also includes Chris Cain, Director of Research at Fairmount, reinforcing the close operational link between Jade and its discovery partner, as well as Lawrence Klein, CEO of Oruka Therapeutics. No recent operational milestones within the last 24 months are publicly verifiable. Jade Biosciences occupies an unusual structural position: it is a clinical-stage company without a disclosed internal research laboratory. Its pipeline depends entirely on licensed assets from Paragon Therapeutics, making it an execution vehicle for Fairmount-backed science. This hub-and-spoke model — a shared antibody engine enabling multiple portfolio-company programs — is a distinct capital-allocation strategy within autoimmune drug development.